GLP 1 Receptor Agonist Cardiovascular Therapy Market Size, Share, Revenue Report 2026 to 2035 What is GLP 1 Receptor Agonist Cardiovascular Therapy Market
5 years of Farxiga usage: Weight loss: 5-8 pounds (maximum amount achievable) Total costs: $30,000 to $36,000 (self-pay) or $1,500 to $6,000 (with insurance coverage) Side effects: Permanent UTIs, recurring yeast infections, increased dehydration risk Outcome after discontinuation: Weight gain back within 3 to 6 months Elimination of diabetes: 0% only possible through managing symptoms Frequency: Every day for years (and potentially a lifetime) Bariatric surgery (one-time surgical procedure): Weight loss: 60-80% of excess body weight Total costs: $15,000 to $25,000 (self-pay), or insurance coverage is often available Side effects: Recovery period post-surgery (2-4 weeks) Long-term outcome: Physiological change
Prepared by FDA-registered, state-board-regulated pharmacies in ISO-classified cleanrooms
Chen: "Youve started the weekly injections, and weve been tracking your weight and hunger patterns
During this period, the most noticeable change is not the number on the scale but how you relate to food
Wegovy (semaglutide) is a GLP-1 receptor agonist administered as a once-weekly subcutaneous injection
